Cyclopamine

Catalog No.S1146

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Cyclopamine Chemical Structure

Cyclopamine Chemical Structure
Molecular Weight: 411.62

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Hedgehog/Smoothened Inhibitors with Unique Features

  • Selective Smoothened inhibitor

    PF-5274857 Smoothened-selective, IC50=5.8 nM.

  • Smoothened Inhibitor in Clinical Trial

    LDE225 (NVP-LDE225,Erismodegib) Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).

  • Newest Smoothened Inhibitor

    GANT61 Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Smoothened Activator

    Purmorphamine Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Product Information

  • Compare Hedgehog/Smoothened Inhibitors
    Compare Hedgehog/Smoothened Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets Smoothened [1]
(TM3Hh12 cells)
IC50 46 nM
In vitro Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
OS-RC-2NY[yTXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnPSI1KSzVyPUWuPFY3PiEQvF2=MYnTRW5ITVJ?
DOHH-2NWPRTVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DLS2lEPTB;OT6zOVY5QSEQvF2=M1XzRXNCVkeHUh?=
no-10M3HNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jEVGlEPTB;OT65NFM6KM7:TR?=MojHV2FPT0WU
LS-513MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzJRW9WUUN3ME2xNU4{PTR5IN88US=>NEnGOmZUSU6JRWK=
ALL-POMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTFzLke3N|Qh|ryPMVjTRW5ITVJ?
8-MG-BAM1zYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrJTWM2OD1zMz6xNVI{KM7:TR?=M2fxZXNCVkeHUh?=
RPMI-8402M2rIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rsSmlEPTB;MUWuPFU{PyEQvF2=MVvTRW5ITVJ?
EoL-1-cellM1nhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rOT2lEPTB;MUiuOVk1QCEQvF2=NFjTTZRUSU6JRWK=
NALM-6MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTF7LkCxOlch|ryPMV;TRW5ITVJ?
DELMoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETqVJZKSzVyPUKwMlE1PzFizszNNUf6cVFrW0GQR1XS
SRNX\aVWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTJ|Lk[3NVUh|ryPNGjBZVhUSU6JRWK=
697MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPWWm11UUN3ME2yOk43OTV3IN88US=>NH3nZmZUSU6JRWK=
COLO-829MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTJ4Lki0PFMh|ryPNFjDT5ZUSU6JRWK=
EVSA-TMmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrDNFFKSzVyPUK3MlU2PjFizszNMnnHV2FPT0WU
ATN-1M2j6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTNzLkKzNlkh|ryPMXHTRW5ITVJ?
L-363NWX5d5ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL5TWM2OD1|MT63OFYyKM7:TR?=NH65cY9USU6JRWK=
LAMA-84MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zYTWlEPTB;M{KuOVIyOSEQvF2=MmfCV2FPT0WU
NOS-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTN2LkK5OVYh|ryPM1\uTXNCVkeHUh?=
BB30-HNCMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvpfGlKSzVyPUO0MlM{ODZizszNMUDTRW5ITVJ?
BC-1NH22fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzQd5ZpUUN3ME2zO{46PzR4IN88US=>M{f2XnNCVkeHUh?=
IST-SL2MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrpSnhNUUN3ME2zPE4zOjRizszNMkfoV2FPT0WU
D-392MGNXPucI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFrvUotKSzVyPUSwMlIzOTVizszNM2HPenNCVkeHUh?=
no-11MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWe2cpFJUUN3ME20NE42PTJzIN88US=>M3PBT3NCVkeHUh?=
LC4-1MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUDkT5FyUUN3ME20NE45PzF4IN88US=>M3nXN3NCVkeHUh?=
A388MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITBZ5VKSzVyPUSyMlU5PDhizszNMonPV2FPT0WU
NTERA-S-cl-D1NF;l[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV[wTHU3UUN3ME20Nk44ODd2IN88US=>MlntV2FPT0WU
CESSNXrNNItFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3m1RmlEPTB;NESuNlI{OiEQvF2=MmfDV2FPT0WU
RS4-11M4rJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPOTWM2OD12OT6wPVM5KM7:TR?=MYHTRW5ITVJ?
MS-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTVyLkmzOVEh|ryPMXnTRW5ITVJ?
CTV-1NH\DbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnv1TWM2OD13MT6wO|Qh|ryPMnHUV2FPT0WU
D-502MGNXT0bIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;nTWM2OD13MT62NlcyKM7:TR?=Mm\6V2FPT0WU
ML-2NGjrS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTV{LkmxPVUh|ryPMl2zV2FPT0WU
SK-NEP-1NGrSTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTV|LkO5NlMh|ryPNH7id4xUSU6JRWK=
LOXIMVIMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLzTWM2OD13Mz61PFg1KM7:TR?=NHrhRmpUSU6JRWK=
DJM-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPiUmxKSzVyPUW2MlM{QTFizszNNXjJWFZtW0GQR1XS
GI-1NXz0NYpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NECxT41KSzVyPUW2MlYyPDlizszNMlP2V2FPT0WU
IST-MES1MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTZyLkW0PVMh|ryPM2foN3NCVkeHUh?=
MV-4-11NWn4fGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vDUGlEPTB;NkCuOlU{QCEQvF2=NEX2dWtUSU6JRWK=
OVCAR-4NET0SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fWU2lEPTB;NkOuOVY2PyEQvF2=M{PXdnNCVkeHUh?=
KE-37M1ruSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[wZWlEPTB;Nk[uNlY3QCEQvF2=NUfDelFsW0GQR1XS
D-542MGNXnEZ5Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUf1cXdtUUN3ME22PE41OTN3IN88US=>NXXhNFhUW0GQR1XS
MHH-PREB-1NYL4OnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHVZ4pKSzVyPUeyMlg1PDFizszNMXHTRW5ITVJ?
MRK-nu-1NXT4ZZFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXkV|RKSzVyPUezMlQ4ODVizszNM1TaUHNCVkeHUh?=
D-247MGNWD6[VJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPVWVNLUUN3ME23N{42PDR{IN88US=>NYnwOGd{W0GQR1XS
OCI-AML2MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVzpR5YzUUN3ME23Ok46OzZ7IN88US=>NVfVZ4J2W0GQR1XS
LP-1MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nUV2lEPTB;OEKuPFc{OSEQvF2=MYLTRW5ITVJ?
HCC1599NInRT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXhTWM2OD16ND6yPFM4KM7:TR?=MWnTRW5ITVJ?
KARPAS-45NEHPT|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7UU5FKSzVyPUi0MlY6QTJizszNMYTTRW5ITVJ?
BE-13MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TLRmlEPTB;OUmuNFQ4PyEQvF2=MYDTRW5ITVJ?
GCIYMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvSSGROUUN3ME25PU4xQTV2IN88US=>M1PqSXNCVkeHUh?=
BV-173MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\acGlEPTB;MUCwMlMzPSEQvF2=M133V3NCVkeHUh?=
LB2518-MELM2nSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3XPRmlEPTB;MUCwMlc5QSEQvF2=Mo\EV2FPT0WU
KS-1MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;jZ2xnUUN3ME2xNFEvPjN7IN88US=>Mo\1V2FPT0WU
MOLT-16NFP3cohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTFyND65PFYh|ryPNVm3PJpqW0GQR1XS
NCI-H1770MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzLToFKSzVyPUGwPE44QDRizszNNVPMSo1{W0GQR1XS
NCI-H82NUTGcW1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnRbm1NUUN3ME2xNVAvQTd4IN88US=>NWD0To1YW0GQR1XS
NCCITM2n0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HMR2lEPTB;MUGyMlUzQSEQvF2=MlHFV2FPT0WU
KALS-1NGjZc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTFzNT65OFEh|ryPMYXTRW5ITVJ?
LB2241-RCCNVzofFhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;ITWM2OD1zMU[uOlc6KM7:TR?=M4nMU3NCVkeHUh?=
HHNXP6d2dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWr2WJV[UUN3ME2xNVcvOzl3IN88US=>MkLLV2FPT0WU
HD-MY-ZMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnhTWM2OD1zMUiuOFg5KM7:TR?=NXX2bm1mW0GQR1XS
EB-3Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLr[VBFUUN3ME2xNlMvODl2IN88US=>M2nGUnNCVkeHUh?=
BL-70MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4O1OmlEPTB;MUKzMlEzPyEQvF2=NYnOXlFNW0GQR1XS
K-562M33obGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzoPVJoUUN3ME2xNlYvOjR3IN88US=>M{LRPHNCVkeHUh?=
HT-144NXnD[2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkDQTWM2OD1zM{OuNVY1KM7:TR?=M3Pub3NCVkeHUh?=
PF-382NGHiWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PuWGlEPTB;MUO0MlM3OSEQvF2=NGHVXFFUSU6JRWK=
RPMI-8226NH\uR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX6yV2JjUUN3ME2xN|UvODR3IN88US=>M4jZfHNCVkeHUh?=
NCI-H1355MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jQZWlEPTB;MUO1MlU5PyEQvF2=M3e0Z3NCVkeHUh?=
LXF-289M1\DT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDETWM2OD1zM{muO|gyKM7:TR?=MYLTRW5ITVJ?
NCI-H69MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfZTWM2OD1zNEKuPVMzKM7:TR?=MYjTRW5ITVJ?
SK-MEL-1MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTF2Nz6xN{DPxE1?NYjNNnFuW0GQR1XS
KARPAS-299NI\He2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrseI9YUUN3ME2xOFkvOTJizszNMUjTRW5ITVJ?
GB-1NX3FUoV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDmTWM2OD1zNEmuN|IzKM7:TR?=NX3pTlhDW0GQR1XS
CMKMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7NbGhKSzVyPUG0PU42OTVizszNNFrOTHlUSU6JRWK=
MPP-89MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPaU4xNUUN3ME2xOVYvODN3IN88US=>MV7TRW5ITVJ?
KU812MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofsTWM2OD1zNkGuPVAzKM7:TR?=NUjSdog2W0GQR1XS
REHNHLFeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF4Mj6xNlUh|ryPMlHhV2FPT0WU
NEC8NUHSRlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TXVGlEPTB;MU[1MlAzPiEQvF2=NFX5T3hUSU6JRWK=
KP-N-YSNFWxdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37jSGlEPTB;MU[4MlM6PSEQvF2=NHr1UpVUSU6JRWK=
Ramos-2G6-4C10Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jv[WlEPTB;MU[5MlkyPSEQvF2=NFnsXnNUSU6JRWK=
BeckerMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfuR3p4UUN3ME2xO|QvOThizszNMXPTRW5ITVJ?
LB647-SCLCM4XZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHnV|VvUUN3ME2xO|UvQDR3IN88US=>MWfTRW5ITVJ?
LU-139MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTF5OD6wNVkh|ryPMVjTRW5ITVJ?
QIMR-WILMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;vW25KSzVyPUG3PU43PDZizszNNGT6cINUSU6JRWK=
NCI-H1395MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzLTWM2OD1zN{muPVk3KM7:TR?=MmDGV2FPT0WU
NOMO-1NYf6[nhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{ixemlEPTB;MUiyMlg2KM7:TR?=MoTSV2FPT0WU
GI-ME-NM{LXUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLpTWM2OD1zOEeuPVY6KM7:TR?=MkS2V2FPT0WU
KMS-12-PENEL5XVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy3eZQ{UUN3ME2xPFkvOjd|IN88US=>Ml35V2FPT0WU
DaudiNHG0OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PaWmlEPTB;MUmxMlEzQCEQvF2=NVHYU|NnW0GQR1XS
LB996-RCCNYj2TWh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHKxV45KSzVyPUG5NU43QTlizszNM1K0NXNCVkeHUh?=
NCI-H2107MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1THfmlEPTB;MUmzMlc{QSEQvF2=NFvsV3VUSU6JRWK=
SK-PN-DWMl7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3mR2lCUUN3ME2xPVQvPzF7IN88US=>M1rDWXNCVkeHUh?=
MC-CARNIPXRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;rV|lsUUN3ME2yNFIvOjV|IN88US=>MmDhV2FPT0WU
SNB75MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzrTWM2OD1{MkGuPVQh|ryPMmnsV2FPT0WU
ES4MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPqTWM2OD1{MkOuO|g{KM7:TR?=MY\TRW5ITVJ?
KARPAS-422NX3UTlZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvFbIdPUUN3ME2yNlgvOzV{IN88US=>MkjFV2FPT0WU
NCI-H1648NHXoPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTaTWM2OD1{MkmuOFg6KM7:TR?=NF7ZXpdUSU6JRWK=
ES6M{TC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELWWm9KSzVyPUKzPU41OyEQvF2=NYnWZ5ZYW0GQR1XS
KNS-81-FDNEHJOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33xRWlEPTB;MkSxMlE6PyEQvF2=M4fxUXNCVkeHUh?=
JARNFflTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfJTWM2OD1{NU[uNlI2KM7:TR?=MVrTRW5ITVJ?
NB1NEf3SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH64RY9KSzVyPUK2NE42OTZizszNMlvzV2FPT0WU
D-336MGNInZe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLrfoFUUUN3ME2yOlAvPjl6IN88US=>M1i1bHNCVkeHUh?=
BC-3NUjzUWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlThTWM2OD1{NkWuNVc5KM7:TR?=NID1c|dUSU6JRWK=
HCC2218NVv0XWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HIOWlEPTB;Mk[2MlQyPSEQvF2=Ml[0V2FPT0WU
TE-9NVOzOIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3e4T2lEPTB;Mk[2MlYzPyEQvF2=MVnTRW5ITVJ?
LB1047-RCCMlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnGcm5KSzVyPUK2Ok44PTNizszNMXrTRW5ITVJ?
CTB-1M1\CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\TXVlwUUN3ME2yOlkvQTd|IN88US=>M3W1b3NCVkeHUh?=
NB7M2nSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zOZmlEPTB;MkexJO69VQ>?MV\TRW5ITVJ?
ST486M3XQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYS3cHBQUUN3ME2yO|cvPDF{IN88US=>NXzz[|dzW0GQR1XS
HCC1187NYTReJpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPkTWM2OD1{OEKuPFEyKM7:TR?=NYPXPJRRW0GQR1XS
NCI-SNU-16MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3TTWM2OD1{OESuNlQ5KM7:TR?=MmD2V2FPT0WU
COR-L279MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlP6TWM2OD1{OUGuOVg1KM7:TR?=MU\TRW5ITVJ?
ES8NX;abXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTJ7ND6xPFIh|ryPMlT4V2FPT0WU
U-698-MNEi1Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDKOG1LUUN3ME2yPVgvOjR|IN88US=>NWPEeHN[W0GQR1XS
HELNYPJbHJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnyeJEyUUN3ME2zNFkvOTR7IN88US=>NVy0O2NiW0GQR1XS
KINGS-1NI\BO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfvWFlKSzVyPUOxNE43PzRizszNNGPhO41USU6JRWK=
KY821MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTN|Nj61PVUh|ryPNUK0TZU1W0GQR1XS
MZ1-PCMknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTN2NT62NVgh|ryPNVK0SG1RW0GQR1XS
LS-411NM1HtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXteGtlUUN3ME2zOVQvPjZizszNNUe0NHZwW0GQR1XS
SIG-M5NVLtfGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3P[JljUUN3ME2zOVkvPzh{IN88US=>NGXvTHBUSU6JRWK=
HTMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[5RZNKSzVyPUO2O{44OTFizszNM2HPeXNCVkeHUh?=
HC-1NU[2[4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojuTWM2OD1|NkeuO|g4KM7:TR?=Ml;hV2FPT0WU
NCI-H1694NEnZPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTN5Mj65N|Qh|ryPM1HtSXNCVkeHUh?=
BB65-RCCNUHZSXhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTN5Nj6yOFUh|ryPMni2V2FPT0WU
HAL-01M4fJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvh[IIzUUN3ME2zO|kvQDN6IN88US=>M2DLZnNCVkeHUh?=
ARH-77M1\afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M32w[GlEPTB;M{m0MlAxQCEQvF2=M1Phd3NCVkeHUh?=
MZ7-melMkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTN7Nz6yN|Mh|ryPNULpWHJNW0GQR1XS
SIMAM4f3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDC[Xd6UUN3ME20NFMvQTN|IN88US=>MYfTRW5ITVJ?
DG-75NVjVUWdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\NV5JKSzVyPUSxOU43QThizszNMX\TRW5ITVJ?
HUTU-80MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4O5cGlEPTB;NEG5MlE5PSEQvF2=MXHTRW5ITVJ?
KNS-42NFL4cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXDO4JKSzVyPUSyOU45OTVizszNMnfFV2FPT0WU
SH-4MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTR{Nz61OlUh|ryPMnjYV2FPT0WU
L-540NUj0SY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVrQNlZmUUN3ME20N|EvODNzIN88US=>MVnTRW5ITVJ?
NB10MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHG4emNKSzVyPUS0NU4zOzRizszNNHf2WlVUSU6JRWK=
ES1NVLhNGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHZbGxKSzVyPUS1Nk44PTNizszNM3PPT3NCVkeHUh?=
KMOE-2MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR3Nj63NVEh|ryPNXLqW5VCW0GQR1XS
MC116MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3yyR2lEPTB;NEW4MlEyPiEQvF2=MVjTRW5ITVJ?
RCC10RGBNVf3V3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTR4MD6wNFUh|ryPMmrrV2FPT0WU
RL95-2NUWzOG44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzqVZRIUUN3ME20OlAvOjN5IN88US=>NHLuR4hUSU6JRWK=
RajiNEf4ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jLXWlEPTB;NE[4MlE1OyEQvF2=MVXTRW5ITVJ?
CAS-1NYTqdXQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPKTnhRUUN3ME20O|IvODd|IN88US=>NH;kNnhUSU6JRWK=
Calu-6MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jneGlEPTB;NEe1MlI3PSEQvF2=MVLTRW5ITVJ?
KG-1M3fxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnZOodvUUN3ME20O|gvPDRizszNMWTTRW5ITVJ?
LB771-HNCMkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlO4TWM2OD12OEKuNlMzKM7:TR?=NWL3eZU1W0GQR1XS
ACNMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTR7Mz61PVkh|ryPNVu3Z2JFW0GQR1XS
KM12MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnqV3VMUUN3ME20PVYvPTh7IN88US=>MmDGV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Hedgehog cell assay This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack

Cell Assay: [2]

Cell lines SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
Concentrations Dissolved in DMSO, final concentration 3 μM
Incubation Time 4 days
Method Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).

Animal Study: [2]

Animal Models Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
Formulation Dissolved in DMSO, and diluted in saline
Dosages 50 mg/kg/day
Administration Subcutaneous injection

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Peukert S, et al. Bioorg Med Chem Lett, 2009, 19(2), 328-331.

[2] Berman DM, et al. Nature, 2003, 425(6960), 846-851.

view more

Chemical Information

Download Cyclopamine SDF
Molecular Weight (MW) 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms 11-deoxojervine
Solubility (25°C) * In vitro DMF 10 mg/mL warming (24.29 mM)
Ethanol 2 mg/mL warming (4.85 mM)
DMSO <1 mg/mL
In vivo 10% DMSO+30% PEG 300+5% Tween 80+ddH2O 1mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Spiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol, 1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-octadecahydro-3',6',10,11b-tetramethyl-, (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Hedgehog/Smoothened Products

  • Smoothened Agonist (SAG) HCl

    Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.

  • SB225002

    SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.

  • SB-334867

    SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.

  • GANT61

    GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Purmorphamine

    Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.

  • LDE225 (NVP-LDE225,Erismodegib)

    LDE225 (NVP-LDE225,Erismodegib) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.

  • Taladegib (LY2940680)

    Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.

  • Glasdegib (PF-04449913)

    Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.

  • SANT-1

    SANT-1 directly binds to Smoothened (Smo) receptor with Kd of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.

    Features:Attenuates SAG stimulation of Shh-LIGHT2 cells to a greater extent relative to other antagonists.

Recently Viewed Items

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us